Felidale 5 mg Coated Tablets for Cats

Main information

  • Trade name:
  • Felidale 5 mg Coated Tablets for Cats
  • Pharmaceutical form:
  • Coated tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Felidale 5 mg Coated Tablets for Cats
    Netherlands
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • thiamazole
  • Therapeutic area:
  • Cats

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0415/002
  • Authorization date:
  • 22-02-2012
  • EU code:
  • UK/V/0415/002
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:May2012

AN:00443/2011

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Felidale5mgCoatedTabletsforCats

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

Activesubstance:

Thiamazole 5mg

Excipients:

TitaniumDioxide(E171) 1.12mg

DispersedSunsetYellowLake15005(E110) 0.10mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Coatedtablet.

Orangesugar-coatedbiconvextablets5.5mmdiameter.

4. CLINICALPARTICULARS

4.1Targetspecies

Cats.

4.2Indicationsforuse,specifyingthetargetspecies

Forthestabilisationofhyperthyroidismincatspriortosurgicalthyroidectomy.

Forthelong-termtreatmentoffelinehyperthyroidism.

4.3Contraindications

Donotuseincatssufferingfromsystemicdiseasesuchasprimaryliverdiseaseor

diabetesmellitus.

Donotuseincatsshowingsignsofautoimmunedisease.

Donotuseinanimalswithdisordersofwhitebloodcells,suchasneutropeniaand

lymphopenia.

Donotuseinanimalswithplateletdisordersandcoagulopathies(particularly

thrombocytopenia).

Donotuseincatswithhypersensitivitytothiamazoleortheexcipient,polyethylene

glycol.

Donotuseinpregnantorlactatingfemales.

Issued:May2012

AN:00443/2011

Page2of6

Pleaserefertosection4.7.

4.4Specialwarnings

Asthiamazolecancausehaemoconcentration,catsshouldalwayshaveaccessto

drinkingwater.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Ifmorethan10mgperdayisrequiredanimalsshouldbemonitoredparticularly

carefully.

Useoftheproductincatswithrenaldysfunctionshouldbesubjecttocarefulrisk:benefit

assessmentbytheclinician.Duetotheeffectthiamazolecanhaveonreducingthe

glomerularfiltrationrate,theeffectoftherapyonrenalfunctionshouldbemonitored

closelyasdeteriorationofanunderlyingconditionmayoccur.

Haematologymustbemonitoredduetoriskofleucopeniaorhaemolyticanaemia.

Anyanimalthatsuddenlyappearsunwellduringtherapy,particularlyiftheyarefebrile,

shouldhaveabloodsampletakenforroutinehaematologyandbiochemistry.

Neutropenicanimals(neutrophilcounts<2.5x10 9 /l)shouldbetreatedwithprophylactic

bactericidalantibacterialdrugsandsupportivetherapy.

Pleaserefertosection4.9formonitoringinstructions.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Washhandsafteruse.

Inthecaseofaccidentalingestion,seekmedicaladviceimmediatelyandshowthe

packageleafletorthelabeltothephysician.

Thiamazolemaycausevomiting,epigastricdistress,headache,fever,arthralgia,

pruritusandpancytopenia.Treatmentissymptomatic.

Washhandswithsoapandwaterafterhandlinglitterusedbytreatedanimals.

Donoteat,drinkorsmokewhilehandlingthetabletorusedlitter.

Donothandlethisproductifyouareallergictoantithyroidproducts.Ifallergicsymptoms

develop,suchasaskinrash,swellingoftheface,lipsoreyesordifficultyinbreathing,

youshouldseekmedicalattentionimmediatelyandshowthepackageleafletorlabelto

thedoctor.

Donotbreakorcrushtablets.

Asthiamazoleisasuspectedhumanteratogen,womenofchild-bearingageand

pregnantwomenshouldweargloveswhenhandlinglitteroftreatedcats.

Pregnantwomenshouldweargloveswhenhandlingtheproduct.

4.6Adversereactions(frequencyandseriousness)

Adversereactionshavebeenreportedfollowinglongtermcontrolofhyperthyroidism.In

manycases,signsmaybemildandtransitoryandnotareasonforwithdrawalof

treatment.Themoreseriouseffectsaremainlyreversiblewhenmedicationisstopped.

Adversereactionsareuncommon.Themostcommonclinicalsideeffectsthatare

reportedincludevomiting,inappetance/anorexia,lethargy,severepruritusand

excoriationsoftheheadandneck,bleedingdiathesisandicterusassociatedwith

Issued:May2012

AN:00443/2011

Page3of6

hepatopathy,andhaematologicalabnormalities(eosinophilia,lymphocytosis,

neutropenia,lymphopenia,slightleucopenia,agranulocytosis,thrombocytopeniaor

haemolyticanaemia).Thesesideeffectsresolvewithin7-45daysaftercessationof

thiamazoletherapy.

Possibleimmunologicalsideeffectsincludeanaemia,withraresideeffectsincluding

thrombocytopeniaandserumanti-nuclearantibodies,and,veryrarely,

lymphadenopathy.Treatmentshouldbestoppedimmediatelyandalternativetherapy

consideredfollowingasuitableperiodforrecovery.

Followinglong-termtreatmentwiththiamazoleinrodents,anincreasedriskofneoplasia

inthethyroidglandhasbeenshowntooccur,butnoevidenceisavailableincats.

4.7Useduringpregnancy,lactationorlay

Laboratorystudiesinratsandmicehaveshownevidenceofteratogenicand

embryotoxiceffectsofthiamazole.Thesafetyoftheproductwasnotassessedin

pregnantorlactatingcats.Donotuseinpregnantorlactatingfemales.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Concurrenttreatmentwithphenobarbitalmayreducetheclinicalefficacyofthiamazole.

Thiamazoleisknowntoreducethehepaticoxidationofbenzimidazolewormersand

mayleadtoincreasesintheirplasmaconcentrationswhengivenconcurrently.

Thiamazoleisimmunomodulatory,thereforethisshouldbetakenintoaccountwhen

consideringvaccinationprogrammes.

4.9Amountstobeadministeredandadministrationroute

Fororaladministrationonly.

The5mgtabletissuitableforcatsrequiringhigherdoserates,ortofacilitate

compliance(seebelow).

Inthelightofrecentstudies,andtheintroductionofa2.5mgtablet,itisrecommended

tousethe2.5mgtabletforstabilisationinthefirstinstance.

Forthestabilisationoffelinehyperthyroidismpriortosurgicalremovalofthethyroid

gland,one2.5mgtabletmorningandevening.Thisshouldensureeuthyroidismwithin3

weeksinmostcases.

Forlong-termtreatmentofhyperthyroidism,thestartingdoseshouldbe2.5mgtwice

daily.After3weeks,thedoseshouldbetitratedtoeffectaccordingtotheserumtotal

T4.Doseadjustmentsshouldbemadebyincrementsof2.5mg.Whereverpossible,the

totaldailydoseshouldbedividedintotwoandadministeredmorningandevening.

Tabletsshouldnotbesplit.Theaimshouldbetoachievethelowestpossibledoserate.

If,forreasonsofcompliance,oncedailydosingwitha5mgtabletispreferable,thenthis

isacceptablealthoughreducedefficacycanbeexpectedcomparedtoatwicedaily

regime.The5mgtabletisalsosuitableforcatsrequiringhigherdoserates.

Ifmorethan10mgperdayisrequiredanimalsshouldbemonitoredparticularly

carefully.Thedoseadministeredmustnotexceed20mg/day.

Forlong-termtreatmentofhyperthyroidismtheanimalshouldbetreatedforlife.

Haematology,biochemistryandserumtotalT4shouldbeassessedbeforeinitiating

treatmentandafter3weeks,6weeks,10weeks,20weeks,andthereafterevery3

monthsandthedosetitratedasnecessary.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Issued:May2012

AN:00443/2011

Page4of6

Intolerancestudiesinyounghealthycats,thefollowingdose-relatedclinicalsigns

occurredatdosesofupto30mg/animal/day:anorexia,vomiting,lethargy,pruritusand

haematologicalandbiochemicalabnormalitiessuchasneutropenia,lymphopenia,

reducedserumpotassiumandphosphoruslevels,increasedmagnesiumandcreatinine

levelsandtheoccurrenceofanti-nuclearantibodies.Atadoseof30mg/daysomecats

showedsignsofhaemolyticanaemiaandsevereclinicaldeterioration.Someofthese

signsmayalsooccurinhyperthyroidcatstreatedatdosesofupto20mgperday.

Excessivedosesinhyperthyroidcatsmayresultinsignsofhypothyroidism.Thisis

howeverunlikely,ashypothyroidismisusuallycorrectedbynegativefeedback

mechanisms.PleaserefertoSection4.6:Adversereactions.

Ifoverdosageoccurs,stoptreatmentandgivesymptomaticandsupportivecare.

4.11Withdrawalperiod

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:antithyroidpreparations:sulphur-containingimidazole

derivatives.

ATCVetCode:QH03BB02.

5.1Pharmacodynamicproperties

Thiamazoleactsbyblockingthebiosynthesisofthyroidhormoneinvivo.Theprimary

actionistoinhibitbindingofiodidetotheenzymethyroidperoxidase,thereby

preventingthecatalysediodinationofthyroglobulinandT

andT

synthesis.

5.2Pharmacokineticparticulars

Followingoraldosinginhealthycats,thiamazoleisrapidlyandcompletelyabsorbed

withabioavailabilityof>75%.However,thereisaconsiderablevariationbetween

animals.Eliminationofthedrugfromcatplasmaisrapidwithahalflifeof4.5-5.0hours.

Peakplasmalevelsoccurapproximately1-2hoursafterdosing.Cmaxisbetween1.6-

1.9μg/ml.

Inratsthiamazolehasbeenshowntobepoorlyboundtoplasmaprotein(5%);40%

wasboundtoredbloodcells.Themetabolismofthiamazoleincatshasnotbeen

investigated,however,inratsthiamazoleisrapidlymetabolisedinthethyroidgland,

withabout64%oftheadministereddosebeingeliminatedintheurineandonly7.8%

excretedinfaeces.Thisisincontrastwithmanwheretheliverisimportantforthe

metabolicdegradationofthecompound.Thedrugresidencetimeinthethyroidgland

isassumedtobelongerthanintheplasma.

Frommanandratsitisknownthatthedrugcancrosstheplacentaandconcentratesin

thefoetalthyroidgland.Thereisalsoahighrateoftransferintobreastmilk.

6. PHARMACEUTICALPARTICULARS

Issued:May2012

AN:00443/2011

Page5of6

6.1Listofexcipients

Tabletcore:

Lactosemonohydrate

Povidone

Sodiumstarchglycollate

Magnesiumstearate

Coating:

Sucrose

Povidone

Dispersedsunsetyellowlake(E110)

Macrogol

Purifiedtalc

Whitebeeswax

Carnaubawax

Shellac

Titaniumdioxide(E171)

Sodiummethylhydroxybenzoate(E219)

6.2Incompatibilities

Notapplicable.

6.3Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:5years.

6.4.Specialprecautionsforstorage

Donotstoreabove25

C.

Keepthecontainertightlyclosedinordertoprotectfrommoisture.

Keepthecontainerintheoutercarton.

6.5Natureandcompositionofimmediatepackaging

Whitepolypropylenetubwithwhitelowdensitypolyethylenetamperevidentlid

containing100tablets.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialderivedfromsuchveterinary

medicinalproductsshouldbedisposedofinaccordancewithlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

Issued:May2012

AN:00443/2011

Page6of6

DechraLimited

DechraHouse

JamageIndustrialEstate

TalkePits

Stoke-on-Trent

Staffordshire

ST71XW

UK

8. MARKETINGAUTHORISATIONNUMBER

Vm10434/4076

9. DATEOFFIRSTAUTHORISATION

2May2012

10.DATEOFREVISIONOFTHETEXT

May2012

21-2-2017

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls a batch of Pamol® in packs of 300 film-coated tablets after the discovery of Ibumetin 600 mg containing ibuprofen in some packs. Both types of medicine are used for the treatment of mild pain, but they work in different ways and may cause different adverse reactions.

Danish Medicines Agency

There are no news related to this product.